A randomized double-blind crossover trial of intravenous lidocaine in the treatment of neuropathic cancer pain

E. Bruera, C. Ripamonti, C. Brenneis, K. Macmillan, J. Hanson

Research output: Contribution to journalArticle


In a randomized, double-blind, crossover study, we evaluated the effect of intravenous lidocaine (5 mg/kg body weight over 30 min) on the neuropathic pain of advanced cancer patients. Pain intensity, assessed by a visual analogue scale, did not show any significant difference between lidocaine and placebo infusion. The blinded choice of patients and investigators also suggested no significant improvement from lidocaine when given by this regimen. Intravenous lidocaine does not appear to have a significant analgesic effect on neuropathic cancer pain.

Original languageEnglish
Pages (from-to)138-140
Number of pages3
JournalJournal of Pain and Symptom Management
Issue number3
Publication statusPublished - 1992


ASJC Scopus subject areas

  • Anesthesiology and Pain Medicine

Cite this